MAIA Biotechnology reports stronger ateganosine data in third-line non-small cell lung cancer
MAIA Biotechnology has reported positive initial efficacy data from Part C of the Phase 2 THIO-101 expansion trial evaluating ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer. The clinical-stage oncology drug developer said the regimen produced a 90.5 percent interim disease control rate among efficacy-evaluable patients, placing its telomere-targeting strategy back in
